| 1 |
33693561 | Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. | 2022 Jan 7 |
1 |
| 2 |
33598678 | BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. | 2021 Jun 24 |
1 |
| 3 |
31286322 | Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. | 2020 Jun |
2 |
| 4 |
31681603 | Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-Targeted Drugs. | 2019 |
1 |
| 5 |
29436642 | Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells. | 2018 Apr |
2 |
| 6 |
29928488 | Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2. | 2018 Jun 1 |
2 |
| 7 |
28619982 | JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. | 2017 Aug 10 |
1 |
| 8 |
26396258 | Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. | 2015 Oct 6 |
1 |